21.2 C
New York
Thursday, June 18, 2026

Tag: cell

US Firm Achieves Second Thorium Breakthrough at Idaho National Lab’s Reactor

CCTE's first-of-its-kind, thorium-based fuel continues to surpass burnup Records, paving the way for safer and more sustainable nuclear power

Vertigenics – The Natural Vertigo Breakthrough Driving 2025 Interest in Balance and Brain Support Formulas

Public Interest in Natural Vertigo Support and Ingredient-First Balance Formulas Continues to Rise in 2025
Public Interest in Natural Vertigo Support and Ingredient-First Balance Formulas Continues to Rise in 2025

Neuro Sharp Gains Recognition in 2025 as Your Ultimate Brain Enhancement Formula

Scientifically Formulated Nootropic Backed by 2025 Research for Sharper Focus and Cognitive Support
Scientifically Formulated Nootropic Backed by 2025 Research for Sharper Focus and Cognitive Support

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update

Woburn, MA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy in dermatology, today reported financial results for the three and six months ended June 30, 2025 and provided a business update.

EV NMC Battery Market to Reach USD 70.8 Billion by 2030, Driven by Rapid Electrification and High-Energy Density Demand | Valuates Reports

What is the Market Size of the EV NMC Battery Market? BANGALORE, India, Aug. 13, 2025 /PRNewswire/ -- The global EV NMC Battery Market was valued...

EV NMC Battery Market to Reach USD 70.8 Billion by 2030, Driven by Rapid Electrification and High-Energy Density Demand | Valuates Reports

What is the Market Size of the EV NMC Battery Market? BANGALORE, India, Aug. 13, 2025 /PRNewswire/ -- The global EV NMC Battery Market was valued...

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT – Advancing Breakthrough Therapy for Chronic Lower Back Pain

PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on regenerative and immune cellular therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead investigational therapy, CELZ-201-DDT, for the treatment of degenerative disc disease (DDD), a major cause of chronic lower back pain and disability.

Hydrogen Market worth $312.90 billion by 2030 | MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 13, 2025 /PRNewswire/ -- The global Hydrogen Market is anticipated to grow from estimated USD 225.12 billion in 2025 to USD...

Hydrogen Market worth $312.90 billion by 2030 | MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 13, 2025 /PRNewswire/ -- The global Hydrogen Market is anticipated to grow from estimated USD 225.12 billion in 2025 to USD...

Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren’s Syndrome in China

YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met...

Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunity

Greywolf starts first trial of GRWD0715, aiming for a functional cure for autoimmunity by targeting its antigenic source.

VEON Completes Sale of Beeline Kyrgyzstan

Dubai, August 13, 2025: VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON”), announces that it has completed the sale of its 50.1% indirect stake in Sky Mobile LLC, operating under the Beeline brand in Kyrgyzstan, to Open Joint Stock Company “Eldik Bank” (“Eldik Bank”). The transaction was completed following receipt of all necessary regulatory approvals.

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCell